Learn More
  • R Widdus
  • Bulletin of the World Health Organization
  • 2001
The global burden of disease, especially the part attributable to infectious diseases, disproportionately affects populations in developing countries. Inadequate access to pharmaceuticals plays a role in perpetuating this disparity. Drugs and vaccines may not be accessible because of weak distribution infrastructures or because development of the desired(More)
  • Roy Widdus
  • Bulletin of the World Health Organization
  • 2003
There are now about 50 public–private partnerships operating internationally to provide the means of combating diseases associated with poverty. Their aim is to develop, or improve access to, health products such as drugs, vaccines, contraceptives, microbicides, diagnostics and bednets. Since getting under way during the last few years, they have been(More)
  • Roy Widdus
  • Transactions of the Royal Society of Tropical…
  • 2005
The development and marketing of medicines needed specifically to combat diseases of the developing world are commercially unattractive because the populations concerned are among the poorest on earth. Partnerships which bring together pharmaceutical companies, academics, not-for-profit organizations, philanthropists, governmental and inter-governmental(More)
The eradication of smallpox and the current polio eradication initiative have provided lessons for future efforts. Currently, control of many diseases through immunisation falls far short of that desirable. To exploit the enormous potential of new vaccines and vaccination technologies, an expanded and more coordinated approach between national governments,(More)